Welcome to our dedicated page for Xenon Pharmaceut SEC filings (Ticker: XENE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Xenon Pharmaceuticals鈥� dense biotech disclosures is no small task; a single 10-K can bury crucial details on epilepsy trial progress, cash runway, and royalty obligations deep inside footnotes. If you鈥檝e ever wondered how to locate "Xenon Pharmaceuticals insider trading Form 4 transactions" or confirm the next XEN1101 milestone payment without skimming hundreds of pages, you鈥檙e not alone.
Stock Titan solves that problem. Our AI reads every 10-K annual report, 10-Q quarterly earnings report, 8-K material event, and Form 4 insider filing the instant they hit EDGAR and delivers plain-English takeaways. Think of it as "understanding Xenon Pharmaceuticals SEC documents with AI"鈥擱&D burn rates, Phase 3 enrollment updates, or executive stock option grants are surfaced in seconds. AG真人官方-time alerts keep you ahead when "Xenon Pharmaceuticals Form 4 insider transactions" post mid-session.
- Xenon Pharmaceuticals quarterly earnings report 10-Q filing with pipeline spend broken down
- Xenon Pharmaceuticals annual report 10-K simplified鈥攔isk factors, cash position, dilution tables
- Xenon Pharmaceuticals executive stock transactions Form 4 and related proxy statement executive compensation
- Xenon Pharmaceuticals 8-K material events explained鈥擣DA feedback, trial pauses, public offerings
- Xenon Pharmaceuticals earnings report filing analysis powered by AI
Whether you鈥檙e tracking "Xenon Pharmaceuticals insider trading Form 4 transactions real-time" before a data readout or comparing sequential R&D spend, our platform condenses complex biotech language into actionable insights. Save hours, reduce uncertainty, and focus on what matters: the science and the numbers.
Xenon Pharmaceuticals Inc. reported results for the quarter ended June 30, 2025. Management states it held $624.8 million of cash, cash equivalents and marketable securities and expects these resources to fund operations for at least the next 12 months. Total assets were $674.3 million and total liabilities were $40.3 million, leaving shareholders' equity of $634.0 million. The company recorded a net loss of $149.8 million for the six months ended June 30, 2025 (net loss of $84.7 million for the three months), and an accumulated deficit of $1,049.2 million.
Research and development spending rose to $136.2 million for the six months, driven by azetukalner program costs (direct costs of $74.9 million). Collaboration revenue of $7.5 million was recognized related to a Neurocrine milestone; NBI-921355 is in Phase 1. Clinically, X-TOLE2 patient recruitment is complete with topline data anticipated in early 2026, and multiple Phase 3 trials (X-TOLE3, X-ACKT, X-NOVA2/3, X-CEED) are underway or enrolling.
Xenon Pharmaceuticals Inc. announced via press release dated August 11, 2025 that it is furnishing its financial results for the three and six months ended June 30, 2025. The press release is attached as Exhibit 99.1 and, per the filing, the information is furnished to the SEC rather than filed.
The company reiterates that it distributes material information through SEC filings, press releases, conference calls, its corporate and investor websites, and social media channels. The filing identifies the company trading as XENE on the Nasdaq Global Market and is signed by Ian Mortimer, Chief Executive Officer and Interim Chief Financial Officer.
Filing: Schedule 13G/A by FMR LLC and Abigail P. Johnson reporting beneficial ownership in XENON PHARMACEUTICALS INC (CUSIP 98420N105). The statement reflects an event date of 06/30/2025 and signature dated 08/05/2025.
Holdings: Aggregate beneficial ownership is 8,824,363 shares, representing 11.5% of the class. On the cover data FMR LLC reports sole voting power of 8,824,348, sole dispositive power of 8,824,363, and zero shared voting/dispositive power. Abigail P. Johnson is reported with sole dispositive power of 8,824,363 and no voting power shown. The filing states the securities were acquired and are held in the ordinary course of business and not to change or influence control of the issuer. Exhibit 99 and Exhibit 24 (power of attorney) are referenced.
Form 3 overview: On 25 June 2025, Xenon Pharmaceuticals Inc. (XENE) filed an Initial Statement of Beneficial Ownership (Form 3) on behalf of newly disclosed officer Darren S. Cline, Chief Commercial Officer. The filing reports the event date as 23 June 2025 and confirms Mr. Cline鈥檚 Section 16 insider status.
Key disclosure: Both Table I (non-derivative holdings) and Table II (derivative holdings) state "No securities are beneficially owned,鈥� meaning Mr. Cline presently holds zero shares or options of Xenon. No amendments, joint filings, or indirect ownership structures are noted. The document is therefore a procedural compliance filing rather than a transaction or compensation event and contains no financial metrics, option grants, or purchase details.
For investors, the absence of insider ownership could be interpreted as a lack of immediate equity alignment, but the filing primarily signals timely regulatory compliance following Mr. Cline鈥檚 appointment.
FAQ
What is the current stock price of Xenon Pharmaceut (XENE)?
What is the market cap of Xenon Pharmaceut (XENE)?
